

**REMARKS/ARGUMENTS**

Claims 1-21 are pending. Applicants have amended page 9 (lines 7 through 10) and page 14 (lines 21 through 27) of the specification. Claim 2 has been amended to reflect the corrections made in the specification.


**Response to Restriction Requirement**

The Examiner has identified a lack of unity in the present application, and has divided the claims into five inventions. Applicants elect to prosecute the invention identified by the Examiner as "II" (claims 2 and 3, drawn to a subset of compounds of Formula I) at this time. As applicants are also being asked to elect a single species, the species corresponding to Compound No. 1 is elected at this time. Claims 2 and 3 are readable on the present species election. Applicants reserve the right to pursue the subject matter of unelected inventions in a future application, and reserve the right to request rejoinder of the application claims as appropriate.

Authorization is hereby provided to charge any required fees to Deposit Account No. 50-0912.

Respectfully submitted,

SALMAN et al.

By:   
George E. Heibel  
Reg. No. 42,648  
Tel.: (609) 720-5334

Date: January 12, 2009

Correspondence Address:  
Ranbaxy Inc.  
600 College Road East, Suite 2100  
Princeton, NJ 08540  
Facsimile: (609) 514-9779